雖然這篇Finerenone patent鄉民發文沒有被收入到精華區:在Finerenone patent這個話題中,我們另外找到其它相關的精選爆讚文章
[爆卦]Finerenone patent是什麼?優點缺點精華區懶人包
你可能也想看看
搜尋相關網站
-
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#1Combination drug comprising finerenone and an nep-inhibitor ...
... drug comprising finerenone and an nep-inhibitor (sacubitril) - Google Patents ... of WO2017029261A1 publication Critical patent/WO2017029261A1/en ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#2Finerenone | US Patents | Expiry | Expiration | Dates
Patents Listed in the FDA Orange Book Drug Database of Finerenone with information and expiry/expiration dates.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#3Finerenone, BAY 94-8862 | New Drug Approvals
PATENT. WO 2016016287. The present invention relates to a novel and improved process for preparing 4- (4-Cyano-2-methoxyphenyl) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#4Finerenone | C21H22N4O3 - PubChem
Finerenone | C21H22N4O3 | CID 60150535 - structure, chemical names, physical and chemical properties, classification, patents, literature, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#5Finerenone - Bayer HealthCare Pharmaceuticals - AdisInsight
As of July 2021, Bayer Healthcare Limited has worldwide patents pending for methods of synthesis of 4-amino-5-methyl-2(1H) pyridine, which is an intermediate ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#6FINERENONE - Inxight Drugs
Structure of FINERENONE SHOW STEREO. ... FINERENONE is a potent and selective nonsteroidal mineralocorticoid receptor antagonist. ... PubMed; Patents ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#7Finerenone and Cardiovascular Outcomes in ... - AHA Journals
Background: The FIDELIO-DKD trial (Finerenone in Reducing Kidney ... and Tricida; he also holds a patent for site-specific delivery of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#8Finerenone in Predominantly Advanced CKD and Type 2 ...
FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease ... to the myocardium (US patent #9931412) and a provisional patent for ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#9Finerenone improves outcomes in patients with mild-to ...
Sophia Antipolis, France – 28 Aug 2021: Finerenone reduces the risk ... to the myocardium (US patent #9931412) and a provisional patent for ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#10Effect of Finerenone on Chronic Kidney Disease Outcomes in ...
Abstract Background Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#11Generic Kerendia Availability - Drugs.com
2022年1月12日 — Generic drug availability, manufacturer information, and patent ... Kerendia is a brand name of finerenone, approved by the FDA in the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#12Cardiovascular and kidney outcomes with ... - Oxford Academic
P.K. is a full-time employee of Bayer AG, Division Pharmaceuticals, Germany. He is a co-inventor of finerenone and holds US and European patents ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#13KERENDIA (finerenone) to Treat CKD Associated with Type 2 ...
KERENDIA (finerenone) is a nonsteroidal mineralocorticoid receptor antagonist indicated for chronic kidney disease associated with type 2 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#14Finerenone - Wikipedia
Finerenone, sold under the brand name Kerendia, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#15Design and Baseline Characteristics of ... - Karger Publishers
However, the effect of finerenone on CV and renal outcomes has not yet ... delivery of eplerenone to the myocardium (US patent #9931412).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#16Bayer Capital Markets Day 2021 Transcript
With Nubeqa, Finerenone and Elinzanetant ... genericization patterns of other small molecules reveal that post patent expiration, sales.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#17Bayer holds its nerve as patent cliff approaches | Evaluate
If Bayer executives are worried about the patent cliff that their pharma unit is ... He pointed to finerenone as a potentially big future ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#18Finerenone Reduces New-Onset Atrial Fibrillation in Patients ...
Patients with CKD and T2D were randomized (1:1) to finerenone or ... and also holds a patent for site-specific delivery of eplerenone to the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#19Finerenone in predominantly advanced CKD and T2D with or ...
由 P Rossing 著作 · 2021 — Finerenone also significantly reduced the kidney (time to kidney failure, ... and Vifor/Relypsa; he also holds a patent for site-specific ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#20Washington, DC 20549 - SEC.gov
We may terminate the agreement if Takeda challenges or opposes any patent covered by ... MR antagonist, finerenone, if and when it is approved by the MHLW.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#21ESC: Finerenone Demonstrates CVD Benefit in FIGARO-DKD
Finerenone bested placebo in the FIGARO-DKD trial, ... He also holds a patent for site-specific delivery of eplerenone to the myocardium (US ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#22public-summary-evaluation-proposed-paediatric-investigation ...
Finerenone for treatment of chronic kidney disease ... protected by a patent, the patent holder has the sole right to make, use, and sell.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#23Bayer data for kidney disease hope finerenone sets up filings -
Bayer data for kidney disease hope finerenone sets up filings ... although patent expirations and the threat of generic competition are ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#24A subgroup analysis from the FIDELIO‐DKD trial - Diabetes ...
Abstract Aims Finerenone significantly reduced the risk of kidney and ... he also holds a patent for site-specific delivery of eplerenone to ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#25Pharmaceutical composition containing a tetrahydrofolic acid
Assignors: KING, KRISTINA: 2008-02-14 Publication of US20080038343A1 publication Critical patent/US20080038343A1/en: 2011-10-11 Assigned to BAYER PHARMA ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#2630. Kerendia | FiercePharma
... a better time for Bayer as it looks to shore up the impeding patent losses of its key sales drivers. ... Active ingredient: finerenone
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#27Drug patent 2028 patent expiry and generic drug entry
Applicant Tradename Generic Name Dosage Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL Impax Labs Inc RYTARY carbidopa; levodopa CAPSULE, EXTENDED RELEASE... Impax Labs Inc RYTARY carbidopa; levodopa CAPSULE, EXTENDED RELEASE...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#28Chronic Kidney Disease - Landscape & Forecast - Clarivate
Patent Intelligence Software · Patent Search & Analytics ... Patient Share of Finerenone by Subpopulation in Chronic Kidney Disease, Major Markets, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#29Nonsteroidal MRA Drug Cuts Risks in Earlier Diabetic Kidney ...
Finerenone (Kerendia) prevents cardiovascular (CV) and some renal events in type 2 diabetes ... He holds patents related to eplerenone and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#30包含吡喃葡萄糖基-取代的苯衍生物的药物组合物 - Google Patents
Info: Patent citations (236); Cited by (75); Legal events ... 2020-04-22 2021-10-28 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#31Finerenone – are we there yet with a non-steroidal ...
The non-steroidal mineralocorticoid receptor antagonist finerenone protects ... expert testimony, grants or patents received or pending, or royalties.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#32Approved Drug Products with Therapeutic Equivalence ...
... and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act) and related patent and exclusivity information.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#33A randomized controlled study of finerenone ... - ScienceOpen
B.P. has received consulting fees for Bayer. Pharma AG, Eli Lilly and Pfizer Inc.; has stock options in Relypsa Inc.; and has a patent pending on site-specific ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#34Bayer seeks US FDA & EMA marketing approval for ...
Bayer seeks US FDA & EMA marketing approval for finerenone to treat chronic kidney disease and type 2 diabetes.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#35Finerenone – Medicines – SPS - Specialist Pharmacy Service
Kerendia · Treatment of diabetic kidney disease in patients with type 2 diabetes mellitus to reduce risk of cardiovascular mortality/morbidity ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#36Finerenone improves outcomes in patients with ... - ScienceDaily
Finerenone reduces the risk of cardiovascular morbidity and mortality in patients with mild-to-moderate kidney disease and type 2 diabetes.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#37Finerenone: Uses, Interactions, Mechanism of Action - DrugBank
Finerenone is a nonsteroidal mineralocorticoid receptor ... Patent Number, Pediatric Extension, Approved, Expires (estimated), Region ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#38Nonsteroidal antagonists of the mineralocorticoid receptor
In contrast, data from two clinical phase II trials are available for finerenone (Bayer) which demonstrated safety and efficacy in patients with heart ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#39Bayer anticipates immediate pharma bounce back after 2024 ...
... division's sales in 2024 due to the patent expirations for estab. ... the brand name Verquvo – and finerenone, along with elinzanetant ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#40Finerenone reduces risk of cardiovascular events in patients ...
Bayer's finerenone reduced the risk of cardiovascular (CV) events in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#415-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox ...
Skip to: Description · Claims · Patent History · Patent History. Description ... Finerenone (I) acts as a non-steroidal antagonist of the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#42Design and Baseline Characteristics of the Finerenone in ...
Finerenone in Reducing Cardiovascular Mortality ... site-specific delivery of eplerenone to the myocardium (US patent. #9931412).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#43(2) Patent Application Publication (10) Pub. No.: US 2016 ...
Patent Application Publication Dec. 8, 2016 Sheet 1 of 20 US 2016/0354315 ... ride, finasteride, finerenone, fingolimod, fipamezole, firte.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#44PATENTS - IP Australia |
the life cycle of an Australian patent and provides certain details of these actions as they relate ... agonist finerenone) from 2-chloro-5-.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#45(PDF) Efficacy and safety of finerenone in patients with chronic ...
PDF | Aims: Finerenone significantly reduced the risk of kidney and ... patent for site-specific delivery of eplerenone to the myocardium.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#46Cardiovascular and kidney outcomes with ... - Abacus
P.K. is a full-time employee of Bayer AG,. Division Pharmaceuticals, Germany. He is a co-inventor of finerenone and holds US and European patents relating to ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#47Enantioselective Total Synthesis of (-)-Finerenone Using ...
Article “Enantioselective Total Synthesis of (-)-Finerenone Using Asymmetric Transfer ... Science and technology information site for articles, patents, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#48Design and Baseline Characteristics of the Finerenone in ...
Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist ... CrossRef - Citation Indexes: 14; Patent Families - Patent Family ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#49Bayer's blockbuster drugs will not bridge revenue gap led by ...
... go off patent, says Stefan Oelrich, the pharma head of the. ... it launched cancer drug Nubeqa and Finerenone, to treat diabetic kidney ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#50Mineralocorticoid receptor antagonists - Journal of ...
apararenone, esaxerenone and finerenone are in late-stage clinical trials in ... Patent. WO 2005087740 A1. Leverkusen, Germany: Bayer Healthcare AG.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#51A subgroup a - HAL Sorbonne Université
and safety of finerenone in patients with chronic kidney disease and ... patent for site-specific delivery of eplerenone to the myocardium.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#52finerenone | C21H22N4O3 | ChemSpider
Structure, properties, spectra, suppliers and links for: finerenone, 1050477-31-0.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#53Finerenone and Cardiovascular Outcomes in Patients With ...
BACKGROUND: The FIDELIO-DKD trial (Finerenone in Reducing Kidney ... also holds a patent for site-specific delivery of eplerenone to the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#54Finerenone and Cardiovascular Outcomes in ... - ReachMD
mineralocorticoid receptor antagonist finerenone on kidney and ... inventor of finerenone and holds US and European patents relating to ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#55Bayer heart failure drug cuts deaths in mid-stage trial | Reuters
Finerenone, which is still several years from reaching the market, is an improved ... The two older medicines, whose patents have expired, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#56Saghmos to launch phase 3 study with patent for ST-62516 ...
Saghmos Therapeutics Inc. announced the issuance of the U.S. Patent No. 11123345 for its product ST-62516, also known as trimetazidine, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#57Bayer Puts Spotlight On Pharma Pipeline - SCRIP Intelligence
... soften the blow of patent expiries on the blockbusters Xarelto and Eylea ... Bayer's Finerenone Stacks Up More CV Benefit Data Ahead Of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#58Bayer scores FDA nod for chronic kidney disease med
... recently that the agency approved Kerendia (finerenone), ... as two of its top sellers — Eylea and Xarelto — near their patent cliff, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#59EP003452463B1* - EP 3 452 463 B1 - European Patent Office
combination with a mineralocorticoid receptor antagonist, for example and preferably finerenone, spironolactone, can-.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#60KDIGO 2020 Clinical Practice Guideline for Diabetes ...
... persistent patent ductus arteriosus, hypocalvaria, limb defects, ... Design and baseline characteristics of the finerenone in reducing ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#61Week In Review | 2021-05-13 | FDAnews
Bayer's Finerenone Shows Promise as Chronic Kidney Disease Treatment ... Despite U.S. Backing, Doubt Persists on Possible Patent Waiver ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#62A randomized controlled study of finerenone vs. eplerenone in ...
less frequently in finerenone-treated patients compared with eplerenone; ... has a patent pending on site-specific delivery of eplerenone to the myo-.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#63After Pharma's Patent Cliff | CHEManager
As the patent cliff peak has worked through the system, big pharma's five-year ... Bayer's diabetic neuropathy project Finerenone and Bristol-Myers Squibb's ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#64Bayer moves into heart failure - Pumping Marvellous
Finerenone is still several years from reaching the market, ... The two older medicines, whose patents have expired, are also linked to kidney problems.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#65the role of finerenone - Semantic Scholar
chronic kidney disease in type 2 diabetes: the role of finerenone. Rajiv Agarwal ... treatment and prevention of organ injury (US patent 63/. 045784).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#66New Bayer drugs will not bridge revenue gap, says pharma ...
... challenge of its two bestselling products going off patent. ... Bayer hopes to launch the second one — a drug called Finerenone to treat ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#67Bayer Sees Three New Blockbusters Driving Pharma Unit's ...
... the blow when two current top-sellers lose patent protection. ... kidney medicine Finerenone and a treatment for menopause symptoms.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#68Bayer announces FDA accepts NDA and grants priority review ...
Finerenone is a potential first-in-class investigational, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that demonstrated ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#69Finerenone significantly reduced renal and cardiovascular ...
Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that demonstrated renal ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#70KDIGO-2020-Diabetes-in-CKD-GL.pdf
respiratory distress syndrome, persistent patent ductus arterio- ... of the finerenone in reducing kidney failure and disease progression in.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#71Bayer's Latest Stage 2 Trial Could Be A Boon For Shares
Finerenone is “an improved version of a troublesome class of heart drugs called ... “The two older medicines, whose patents have expired, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#72Patent expiries loom as Bayer looks to mid-2020s for return on ...
The other pharmaceutical products Bayer is pinning its blockbuster hopes on are finerenone, a mineralocorticoid receptor antagonist that the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#73Rationale and design of MinerAlocorticoid Receptor...
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#74Bayer Annual Report 2019 - RegInfo
Crop Science regularly applies for patent protection for its new crop protection active ingredients ... Finerenone (MR antagonist).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#75Polymer-based sustained release device - Google Patents
PATENT SECURITY AGREEMENT (SECOND LIEN) Assignors: ALKERMES CONTROLLED ... Combination of finerenone and a sglt2 inhibitor for the treatment and/or ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#76CURRENT - Nonsteroidal antagonists of the mineralocorticoid ...
are available for finerenone (Bayer) which demonstrated safety and ... In this review article, the authors give a comprehensive overview of patents on MRA.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#77Advances in the Development of Non-steroidal ... - IntechOpen
... named finerenone ( 17 , see Figure 5), entered clinical trials. DHP has also been the focus of Merck, which patented a series of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#78Phase IIb Safety and Efficacy Study of Different Oral Doses of ...
Condition or disease, Intervention/treatment, Phase. Heart Failure, Drug: Finerenone (BAY94-8862) Drug: Placebo Drug: Inspra (eplerenone), Phase 2 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#79India upholds compulsory licence on cancer drug in Bayer ...
The decision confirms that the Indian patent office is able to use all the means legally at its disposal to check the abuse of patents and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#80có kèo nhà cái - Tạp chí Tia Sáng
Theo Yaozhi Patent Communication, ngày hết hạn sớm nhất của bằng sáng ... loại thuốc thử nghiệm Finerenone của họ để điều trị bệnh thận mãn ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#81EU Green Light for Finerenone for CKD, Growth Hormone for ...
Positive opinions issued for branded somatrogon and finerenone and for generic versions of sitagliptin/metformin hydrochloride and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#82Flow Chemistry in Drug Discovery - 第 364 頁 - Google 圖書結果
Few patents describe a synthetic route as well as purification of this medicine. ... Overall, the patent reports that up to 200 kg of Finerenone can be ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#83Patent register
Patent register. From Health Canada. This information is provided by an organization which is not subject to the Next link will take you to ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#84Cardiovascular Outcomes With Finerenone in Patients With ...
Dr. Scirica: FIDELIO-DKD was a study with a drug called finerenone, which is a selective, nonsteroidal, mineralocorticoid receptor antagonist.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#85Aldosterone - 第 175 頁 - Google 圖書結果
The discovery of finerenone also started from screening of the company ... Multiple patent applications disclose exploration of the SAR of the DHP ring ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#86Encyclopedia of Endocrine Diseases - 第 693 頁 - Google 圖書結果
Indeed, very recently new molecules have been patented in the ... finerenone) calcium channel blockers with mineralocorticoid receptor antagonist properties ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#87Aldosterone-Mineralocorticoid Receptor: Cell Biology to ...
... named finerenone (17, see Figure 5), entered clinical trials. DHP has also been the focus of Merck, which patented a series of sub-micromolar binding ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#88Notice of Compliance (NOC) Database - Canada.ca
... Find a patent · Import and export from Canada · Name a business · Make changes to your corporation (Online Filing Centre). Benefits.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?>
finerenone 在 コバにゃんチャンネル Youtube 的最讚貼文
finerenone 在 大象中醫 Youtube 的最佳貼文
finerenone 在 大象中醫 Youtube 的最佳解答